Although there are more than 12 antibodies conjugated to FDA-approved drugs, their effectiveness in solid tumors is limited due to low tumor penetration. In this work we propose to use molecular imaging techniques to obtain drug-conjugated miniproteins with improved in vivo properties. Being 20 times smaller than antibodies, miniproteins are expected to have greater tumour penetration and also greater effectiveness.